News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
Xlife Sciences AG announces transition to the main segment of SIX Swiss Exchange to strengthen market presence, with advantages like increased visibility, improved liquidity, and stronger recognition in capital markets -
COMMUNIQUÉ DE PRESSE
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
MindMaze Therapeutics Holding SA outlines a global reimbursement strategy for next-generation neurotherapeutics, focusing on scalability and sustainable growth across major healthcare systems -
COMMUNIQUÉ DE PRESSE
Elis strengthens its network through the acquisition of Adrett in Germany
Elis acquires Adrett Textilservice GmbH Wäscherei und Reinigung in Germany, expanding its network. Acquisition revenue of €12 million to be consolidated in 2026 revenue. Elis, a global circular services leader, strengthens position in the German market -
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma, showing significant reduction in exacerbations and improved lung function in phase 3 studies -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
Le Dupixent de Sanofi et Regeneron a été approuvé au Japon pour traiter l'asthme bronchique chez les enfants de 6 à 11 ans, avec des résultats positifs sur les exacerbations et la fonction pulmonaire
